Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
Clinical trial NCT02447887 · TERMINATED
Trial details
- NCT number
- NCT02447887
- Sponsor
- Fox Chase Cancer Center
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-08-14
- Primary completion
- 2017-04-25
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.